Royalty Pharma plc (NASDAQ: RPRX)

Royalty Pharma plc, also known by its stock symbol RPRX, operates in the biopharmaceutical industry as the largest buyer of biopharmaceutical royalties and a leading funder of innovation. The company has been a pioneer in the royalty market since its inception in 1996, collaborating with various partners including academic institutions, research hospitals, not-for-profits, and leading global pharmaceutical companies. Royalty Pharma's business model focuses on the most attractive aspects of the biopharmaceutical industry, capturing long product life cycles, significant barriers to entry, and non-cyclical revenues through the acquisition of royalties on approved products or development-stage product candidates that have generated strong proof of concept data.

The company's portfolio is made up of royalties on more than 35 commercial products and 14 development-stage product candidates, with a focus on acquiring royalties on the most attractive therapies across the industry. Royalty Pharma's portfolio includes royalties on products such as Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT, and Gilead's Trodelvy, among others. These royalties are protected by long patent lives, with an estimated weighted average duration of approximately 13 years based on projected cumulative cash royalty receipts.

Royalty Pharma's competitive advantage lies in its disciplined approach to acquiring both approved and development-stage product candidates, based on a framework of key product success factors. These factors include strong scientific rationale, significant impact on patients and/or caregivers, conviction in probability of clinical and regulatory success, mission and execution-oriented management team, strong marketer and global commercial opportunity, clear commercial positioning, potential for multiple indications or label expansion, first-in-class or best-in-class, and compelling value proposition for government and commercial payors. The company's success is also contingent on factors such as the effectiveness, safety, and side effect profile, price, market acceptance, manufacturing, supply and distribution, governmental regulation, intellectual property protection and exclusivity, and product liability claims.

In 2023, Royalty Pharma generated $3.0 billion of Portfolio Receipts and announced transactions with a total potential value of $4.0 billion. The company deployed $2.2 billion of cash to acquire royalties, milestones, and other contractual receipts in 2023, paid dividends of $358.3 million, and repurchased shares for $304.8 million. The company's portfolio is highly diversified across products, therapeutic areas, and marketers, with no individual product accounting for more than 23% of its Portfolio Receipts.

Royalty Pharma's mission is to accelerate innovation in life sciences and positively impact patient lives globally. The company partners with innovators such as academic institutions, research hospitals, nonprofits, and companies at the forefront of discovering lifesaving therapies to improve human health through solutions tailored to the needs of its partners. The company's corporate responsibility strategy, policies, and practices aim to create sustainable long-term value for its company, its employees, its shareholders and other stakeholders, while also helping it reduce risk and identify new opportunities.

Royalty Pharma's brand names and/or trade names of its products and services include Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT, and Gilead's Trodelvy, among others.